Core Viewpoint - Clover Biopharmaceuticals-B (02197) announced positive preliminary data from two ongoing clinical trials utilizing its proprietary and fully validated Trimer-Tag vaccine development platform for evaluating its PreF respiratory combination vaccine candidates (RSV+hMPV±PIV3) [1] Group 1: Clinical Trials - The first Phase I clinical trial is being conducted in Australia to assess the combination vaccine candidates SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3) against SCB-1019 (Clover's RSV candidate vaccine) in a head-to-head comparison among elderly participants who have not received any RSV vaccine previously [1] - The second Phase I clinical trial is taking place in the United States, evaluating SCB-1019 (Clover's RSV candidate vaccine) against AREXVY (GSK's RSV vaccine) in a head-to-head assessment among elderly participants who have received at least one dose of AREXVY in the two preceding flu seasons [1]